Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.98 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.98 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.98 |
| ▸ | RET | P07949 | 5/20 | 0.98 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.98 |
| ▸ | KIT | P10721 | 4/20 | 0.98 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.98 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.98 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.98 |
| ▸ | STK10 | O94804 | 2/20 | 0.98 |
| ▸ | ABL1 | P00519 | 2/20 | 0.98 |
| ▸ | BCR | P11274 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.98 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.98 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenvatinib SCHEMBL29349806 | 0.99 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29372021 | 0.99 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL864638 | 0.99 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL865174 | 0.96 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29357626 | 0.96 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29368684 | 0.96 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL3928020 | 0.94 | FGFR4 (0.91) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL28586143 | 0.94 | FGFR4 (0.91) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL1248140 | 0.92 | FGFR4 (0.87) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL30083661 | 0.92 | FGFR4 (0.86) | FGFR4KDRFGFR1PDGFRARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567955-A3 | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2567955-A2 | Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these | Eisai R&D Management Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
| JP-2010280713-A | CRYSTAL OF SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINOPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR SOLVATE THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R & D MANAGEMENT CO LTD | 2010-12-16 | — | — | JP | disclosed |
| US-7612208-B2 | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1698623-A1 | CRYSTAL OF SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINO-PHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR OF SOLVATE THEREOF AND PROCESSES FOR PRODUCING THESE | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | AQP4, UACA, AQP3 | KDR 3394/4885FLT1 3838/4885FLT4 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.